Successfully Integrate Minimal Residual Disease (MRD) Assessment in Clinical Trials to Enable Earlier Treatment Interventions and More Accurate Dosing Regimens, Thereby Enhancing Precision Therapies and Improving Patient Outcomes. Time: 8:00 am to 3:45 pm. Prices: USD 0.50 - USD 3699.00. Speakers: Angela Silvestro, Director - Companion Diagnostics, GSK, David Yu, Director - Precision Medicine and Translational Medicine, Bristol Myers Squibb and more